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Heparin is a linear sulfated polysaccharide widely used therapeutically as an anticoagulant. It is also the
starting material for manufacturing low-molecular-weight heparins (LMWH). Quality control of heparin
and LMWH is critical to ensure the safety and therapeutic activity of the ﬁnal product. However due to
their complex and heterogeneous structure, orthogonal analytical techniques are needed to characterize
the building blocks of heparin. One of the state-of-the-art methods for heparin analysis is based on com-
plete enzymatic digestion using a mixture of heparinases I, II, and III, followed by the separation of the
resulting oligosaccharides by liquid chromatography. The European Pharmacopoeia strong anion-
exchange chromatographic method, used to quantify 1,6-anhydro derivatives in enoxaparin, is here
applied to the analysis of the heparin building blocks. Their quantiﬁcation, namely the determination
of their average w/w percentage in the heparin chain, is obtained after identiﬁcation of all components
including glycoserine derivatives and 3-O sulfated di- and tetrasaccharides. This work therefore provides
a comprehensive overview of the building blocks of unfractionated heparin, including those chemically
modiﬁed by the manufacturing process, either within the polysaccharide chain or at its reducing end.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Heparin is a highly sulfated polymeric linear chain with repeat-
ing disaccharide units comprised of an uronic acid (glucuronic or
iduronic) and a glucosamine. Heparin is widely used as an antico-
agulant in the treatment of thromboembolic diseases either as
unfractionated heparin, or as the starting material for the synthesis
of low-molecular-weight heparins (LMWH).
Heparin can be extracted from various tissues in pigs, cattle,
and sheep, including the lung, intestine, or skin. Although the Euro-
pean Pharmacopoeia (Ph. Eur) [1] and U.S. Pharmacopeia (USP) [2]
specify that only heparin derived from porcine intestinal mucosa
can be used as the starting material for manufacturing LMWH,
bovine or ovine heparins can be found in industrial quantities
necessitating the use of appropriate analytical methods to detect
a potential contamination. At the end of 2007, the adulteration of
heparin by oversulfated chondroitin sulfate (OSCS) resulted in sev-
eral fatal issues during in its clinical use [3], further highlighting
the importance of the quality control of heparin. The objectives
of this quality control should address several issues: it must ﬁrst
assess the anticoagulant activities, enable discriminant structural
characterization of the product, and detect potential contamina-tion. However the analysis of heparin is very complex because hep-
arin is a mixture of polydisperse heteropolymers with a high
molecular weight (10,000–20,000 Da). No single method has sufﬁ-
ciently high-resolving power to characterize its structure, making
the use of a set of orthogonal methods necessary; this is also true
in the case of LMWH. The Ph. Eur. and USP monographs require 1H
NMR spectroscopy, strong anion exchange (SAX) chromatography,
and molecular weight characterization by gel permeation chroma-
tography; yet, these methods do not allow a precise structural
assessment of the heteropolymer composition.
The use of enzyme lyases such as heparinases to depolymerize
the glycan into building blocks that can be fully characterized by
chromatography, is a technique of major interest as it is simple
and informative. Although it remains far from being able to illus-
trate the true complexity of heparin or LMWH, this technique
can provide a ﬁrst insight into the heparin source (crude or pure
heparin), its composition consistency, the animal species of origin,
and potential contamination. Moreover, it can detect structural
modiﬁcations to heparin and can therefore be used to monitor
the chemical transformations that occur during the heparin manu-
facturing process. Currently, although this method indirectly
appears in the USP and Ph. Eur. enoxaparin monographs for the
control of 1,6-anhydro derivatives [5,6,14], it is not included in
the current heparin monographs, nor is it recommended in the
FDA guideline [4]. Previous publications have referred to this
Abbreviations for saccharide units and chemical modiﬁcations
U uronic acid
IdoA L-iduronic acid
GlcA D-glucuronic acid
DU 4,5-unsaturated uronic acid, e.g. DGlcA
GlcN D-glucosamine
NS N-sulfate
NAc N-acetyl
2S 2-O-sulfate
6S 6-O-sulfate
GalA D-galacturonic acid
Structural symbols
DIVa DU-GlcNAc
DIVs DU-GlcNS
DIIa DU-GlcNAc,6S
DIIIa DU2S-GlcNAc
DIIs DU-GlcNS,6S
DIIIs DU2S-GlcNS
DIa DU2S-GlcNAc,6S
DIs DU2S-GlcNS,6S
DIVsgal DGalA-GlcNS
DIIsgal DGalA-GlcNS,6S
IIsglu GlcA-GlcNS,6S
IIIsid IdoA2S-GlcNS
IVsglu GlcA-GlcNS
IIaid IdoA-GlcNAc,6S
IIIaid IdoA2S-GlcNAc
Iaid IdoA2S-GlcNAc,6S
Isid IdoA 2S-GlcNS,6S
The iduronic (id) or glucuronic (glu) structure of uronic
acids is indicated for oligosaccharides, e.g. DIs–IIIsid.
Underlined disaccharides have a 3-O-sulfated glucosamine,
e.g. IIsglu (GlcA-GlcNS,3S,6S).
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provide precise and comprehensive description of this important
and rather simple analytical tool.
The cleavage of the heparin glycosidic linkages by heparinases
generates, after b-elimination, a new oligosaccharide with a D-4-
5 unsaturated uronic acid at its non-reducing side. When the 3
heparinases are applied together, 8 major unsaturated disaccha-
rides [22,23] are formed, with varying sulfation patterns in posi-
tion C-2 and C-6 and on the glucosamine either N-sulfated or
N-acetylated. In addition, longer oligosaccharides resistant to hep-
arinases, such as 3-O sulfated tetrasaccharides, are generated
[9–11]. Similarly, glycoserine tetrasaccharides, residues of the hep-
arin–glycoprotein linkage and also heparinase-resistant are
observed [12,13]. Some methods for the quantitative analysis
of heparin and LMWH digests have already been developed [15–
19]. However these have important limitations such as insufﬁcient
resolution, incomplete elution of the components mixture, or frag-
mentary achievement of the quantitative aspect. They also include
ﬂuorescent tagging on the saccharide reducing-end to increase
detectability, which is justiﬁed for low-concentration biological
samples but is inappropriate and a source of potential error for
heparin samples where the UV absorbance of unsaturated acids
at 232 nm is sufﬁcient for detection. Moreover, the labeling efﬁ-
ciency of substrates is often variable (e.g. null for 1,6-anhydro
derivatives) and side reactions can occur, further increasing the
complexity of the sample analysis.
Quantiﬁcation methodology using external standards is hard to
implement due to the number of components, the time necessaryto purify standards, and the expected precision associated with
the purity of these standards. The most suitable alternative for
quantiﬁcation is internal standardization. Two previously pub-
lished quantitative methods use DIp (DU2S-GlcNCOEt,6S) as inter-
nal standard and ﬂuorescent tagging by 2-aminoacridone [16,18].
In the ﬁrst one [16], capillary electrophoresis is used, but the selec-
tivity is insufﬁcient to resolve all components of heparin digests. In
the second one [18], the separation is performed by reversed-phase
chromatography, identiﬁcation by mass spectrometry (MS) and
quantiﬁcation by double UV detection. A method of quantitation
by LC–MS [19] using isotopic internal standards chemo-enzymati-
cally prepared is also described, but this method cannot be applied
in a control laboratory.
In the method described in this paper, the quantiﬁcation is
based on the data driven consensus assumption that molar extinc-
tion coefﬁcient at 232 nm for D-4-5 unsaturated oligosaccharides
are constant [8]. However, to apply this rule to heparin digests, it
is necessary to identify every components of the digest to assess
their molecular weights. We thus describe here a comprehensive
method to identify and quantify the building blocks of heparin
generated by heparinase digestion. All natural components (disac-
charides and tetrasaccharides) and other major features generated
by the heparin puriﬁcation process are reported.
2. Material and methods
2.1. Materials
All heparin samples used in this study were extracted from por-
cine mucosa. Puriﬁed heparin samples were obtained from differ-
ent sources available on the industrial market. All enzyme lyases
from Flavobacterium heparinum (heparinase I [EC 4.2.2.7], heparin-
ase II [no EC number], and heparinase III [EC 4.2.2.8]) were
obtained from Grampian Enzymes (Aberdeen, UK). All other
reagents and chemicals were of the highest quality available.
Water was puriﬁed using a Millipore Milli-Q puriﬁcation system.
2.2. Enzymatic digestion
Heparin digestion (20 lL of a 20 mg/mL solution in water) was
performed at room temperature for 48 h, in a total volume of
160 lL containing 20 lL heparinase I, II, and III mixture (0.5 IU/
mL of each heparinase in a potassium phosphate buffer pH 7.0
[10 mM KH2PO4 and 0.2 mg/mL of bovine serum albumin(BSA)])
and 120 lL of 100 mM sodium acetate buffer (pH 7.0) containing
2 mM of Ca(OAc)2 and 0.1 mg/mL BSA.
2.3. Analysis of heparin digests by SAX chromatography
Exhaustively-digested heparin (4–10 lL) was injected onto a
Spherisorb-SAX chromatography column (250  3.2 mm, 5 lm,
column temperature 50 C, Waters, France). Mobile phase A was
1.8 mM NaH2PO4 at pH 3.0 and mobile phase B was an aqueous
solution of 1.8 mM NaH2PO4 with 1 M NaClO4 adjusted to pH 3.0.
A linear gradient of mobile phase B (t0 min 3%; t20 min 35%; t50 min
100%) was applied with a ﬂow rate of 0.45 mL/min. Double UV
detection was performed at 232 nm and 202–247 nm. N-acetylated
oligosaccharide selective signal (202–242 nm) is the result of the
subtraction of the 202 nm wavelength signal from the 247 nm ref-
erence signal, as previously described [10].
2.4. Analysis of heparin digests by LC/MS
Heparin digests were injected on ion-pair LC/MS chromatogra-
phy using experimental conditions derived from those described
by Doneanu et al. [20]. Brieﬂy, Acquity UPLC BEH C18 column
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used. Mobile phase A was water and mobile phase B was
water:acetonitrile (25:75) and both mobile phases contained
15 mM of pentylamine or hexylamine (PTA or HXA, ion-pairing
reagents) and 50 mM 1,1,1,3,3,3-Hexaﬂuoro-2-propanol (HFIP;
buffering agent) with a ﬂow rate 0.25 mL/min.
Electrospray ionization mass spectra were obtained using a
Xevo Q-Tof MS (Waters). The electrospray interface was set in posi-
tive-ion mode with a capillary voltage of 2000 V and a sampling
cone voltage of 20 V. The source and the desolvation temperatures
were 120 C and 400 C, respectively. Nitrogen was used as desolv-
ation (750 L/min) and cone gas (25 L/min). The mass range was
200–2000 Da (scan rate 0.5 s). Under these conditions, molecular
ion peaks were adducts of the ion-pairing agent (PTA or HXA).
The number of adducts and their molecular weight was obtained,
as described previously [21], by running a ﬁrst injection with
PTA and a second injection with HXA.
3. Results and discussion
Heparin is present in various animal tissues as a proteoglycan
where the polysaccharide chain is linked to a ser-glycine core pro-
tein through the glycoserine sequence -GlcA b1-3 Gal b1-3 Gal b1-
4 Xyl b1-0-Ser, which is the biosynthesis starting point. In the ﬁrst
step of the manufacturing process, the protein is eliminated by
proteolysis in alkaline environment. Crude heparin is then
obtained by treatment with anion exchange resins or precipitation
with quaternary ammonium salts.
In the second step, the puriﬁcation of crude heparin eliminates
all by-products (protein, peptide, DNA and dermatan) co-extracted
with heparin. Notably, this step involves treatments in strong alka-
line media as well as the use of oxidizing agents such as potassium
permanganate, peracetic acid and hydrogen peroxide. It is duringFig. 1. LC–MS analysis of a crude mucosa heparin (a) compared withthis second phase that most of the structural modiﬁcations of the
endogenous heparin backbone occur.3.1. Identiﬁcation of endogenous oligosaccharide building blocks
The most exact image of endogenous heparin can be found in
some crude heparins, especially those with limited alkaline treat-
ment. The main oligosaccharide components found in these hepa-
rin digests, excluding the 8 main unsaturated disaccharides will be
described ﬁrst.
The original glycoserine tetrasaccharide DGlcA b1-3 Gal b1-3
Gal b1-4 Xyl b1-0-Ser (DGlyser) [12,13] was present in almost all
crude heparins. This compound is cleaved by heparinase III [12]
and, as it contains no sulfate, has the lowest retention on SAX chro-
matograms. Although 85% of the heparin chains are depolymerized
into disaccharides, more complex heparinase-digestion behavior
is observed with 3-O-sulfated moieties. Depending on the saccha-
ridic environment, 3-O-sulfated moieties can be digested into
tetrasaccharides or, more rarely, into disaccharides (DIIs and
DIs). The heparin-resistant tetrasaccharide (DIs–IIsglu) [24] was
ﬁrst isolated from a digest of bovine lung heparin by heparinase
I, but has also been detected in porcine mucosa heparin. Three
other 3-O-sulfated tetrasaccharides (DIIa–IIsglu, DIIa–IVsglu, and
DIIs–IIsglu) were isolated from porcine mucosa heparin by enzy-
matic digestion with heparinase I and II [9]. A more exhaustive
insight into the heparin digest by the heparinase mixture, as
assessed by cetyltrimethylammonium-SAX chromatography, has
been published [10]. However the porcine heparin used in this ear-
lier study was puriﬁed and some unidentiﬁed tetrasaccharides
observed, possibly mistaken for unknown 3-O sulfated derivatives,
might in fact have been residues of heparin partially transformed
by the puriﬁcation process.a puriﬁed heparin (b) depolymerized by the heparinase mixture.
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sulfated di and tetrasaccharides characteristic of porcine mucosa
heparin, a liquidchromatography/mass spectrometry (LC–MS)chro-
matogramof a digested crudeheparin is shown in Fig. 1a. In addition
to the 3-O-sulfated tetrasaccharides previously isolated, we identi-
ﬁed DIa–IIsglu [10], as well as two 3-O-sulfated disaccharides (DIIs
and DIs). The tetrasulfated disaccharide DIs was ﬁrst isolated from
bovine intestinal heparin sulfate [26]. Itwas then isolated in an octa-
saccharide from semuloparin [27] an ultra-LMWH prepared from
porcine mucosa heparin. The presence of DIa–IIsglu is also in direct
agreementwith results already obtainedbynitrous acid depolymer-
ization [25]. Two fragments corresponding to Isid (Mw 595) and
GlcNS–Isid (Mw 916) are residues of the original non-reducing end
of the heparin chain. A similar saturated minor fragments (+18 Da)
can be detected for major unsaturated disaccharides of themixture,
all originating from the non-reducing end. These compounds
accounts globally for about 4% in the heparin polysaccharide chain
(1 disaccharide out of 25; taking into account that the heparinmean
molecularweight is about 15,000 Da and the averagemeanmolecu-
lar weight of a disaccharide is 600 Da). The inﬂuence of this non-
reducing sequence had a negligible effect on the percentage of each
building block in the heparin chain.
3.2. Identiﬁcation of ﬁngerprint building blocks found in digests of
puriﬁed heparin
In contrast with the compounds cited in the previous section,
some oligosaccharides detected in puriﬁed heparin are not present
in crude heparin and were speciﬁcally generated by side reactionsFig. 2. SAX chromatograms of the 3 puriﬁed heparin batches depolymerized by the hepar
202–242 nm. (For interpretation of the references to colour in this ﬁgure legend, the reathat occur during the puriﬁcation step. The increased complexity of
the LC–MS chromatogram in Fig. 1b, compared with Fig. 1a, sug-
gests that these oligosaccharides are numerous and very difﬁcult
to fully identify. When puriﬁed heparin digests are separated by
the Spherisorb-SAX method (Fig. 2), new components were also
detected (Fig. 2; arrows 1–5).
The processes during heparin puriﬁcation that generate struc-
tural modiﬁcations are not just linked to an alkaline environment,
but can also be linked to the oxidation reagents. Some of these
modiﬁcations have already been studied and identiﬁed [28,33] as
they give a 1H NMR extra signal that could interfere with potential
signals characteristics to the OSCS contamination [2].
We have previously demonstrated that peak 1 on Fig. 2 is the
tetrasaccharide responsible for the 2.10 ppm NMR extra signal
detected in KMnO4-treated heparins [28]. Other labeled oligosac-
charides in Fig. 2 have yet to be identiﬁed. Thus, in puriﬁed hepa-
rin, a signiﬁcant proportion of the oligosaccharides eluted after DIs
are not 3-O-sulfated tetrasaccharides, but process-modiﬁed
oligosaccharides.3.2.1. Glycoserine derivatives
The oxidizing step during the second phase of the heparin pro-
cess is generally used to decrease the coloration of the drug prod-
uct. Chemically, we observed that the glycoserine reducing-end is
denatured into characteristic ﬁngerprints that speciﬁcally reﬂect
the oxidation conditions (reactant, stoichiometry, temperature)
[13]. To investigate structural modiﬁcations, glycoserine fragments
were isolated in the heparin digests and identiﬁed by MS and NMRinase mixture (focus on the elution of tetrasaccharides). Black line: 232 nm; red line:
der is referred to the web version of this article.)
Table 1
Heparin derivatives identiﬁed.
Endogenous glycoserine
DGlyser
Non-endogenous glycoserine derivatives
DGlyserox1
DGlyserox2
Other non-endogenous derivatives
DISO3 [29]
Tetrasaccharide A DIs-I2SO3
Tetrasaccharide B DI2SO3-Isid
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the Supporting Information.
3.2.2. Other derivatives
The second step of the heparin manufacturing process, namely
puriﬁcation in oxidative and alkaline media, is usually designed to
have limited impact on the structure of the oligosaccharidic chain.
However, alkaline media can cause side reactions, such as the par-
tial 2-O-desulfation of iduronic acids detected in the digest [30]
especially when conditions are not well controlled. The 2 main
markers of 2-O-desulfation in heparin digests are derivatives of
galacturonic acid: DIIsgal and DIVsgal.
A D4,5-uronic acid with a 2-sulfonic acid substitution has also
been reported previously [29]. This compound was also identiﬁed
in selected heparin batches in the present study and designated
DISO3 (Table 1). Two tetrasaccharide precursors of this sulfonic
disaccharide were also identiﬁed in a rejected enoxaparin sample:one with the sulfonic disaccharide at the reducing-end (Tetrasac-
charide A); the other with the sulfonic disaccharide at the non-
reducing-end (Tetrasaccharide B) (Table 1). NMR spectra for these
tetrasaccharides are provided in the Supporting Information. It is
interesting to note that the NMR signal characteristic of sulfonic
disaccharides inside the heparin chain has chemical shifts corre-
sponding to Tetrasaccharide A.
3.3. Elution of oligosaccharide building blocks
Fig. 3 shows the molecular weights of peaks according to their
identiﬁcation on the chromatogram. Other examples of chromato-
grams of heparin depolymerized batches are given in Fig. 4. In con-
trast with the sample shown in Fig. 3, which still contains its native
glycoserine linking region, the example in Fig. 4a included two
denatured residues, namely DGlyserox1 and DGlyserox2, which
result from potassium permanganate oxidation; DISO3, described
Fig. 3. Heparin batch depolymerized by heparinase mixture and molecular weights applied for the quantiﬁcation. Black line: 232 nm; red line: 202–242 nm. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Heparin batches a and b (porcine intestinal mucosa) depolymerized by heparinase mixture. Black line: 232 nm; red line: 202–242 nm. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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serox1 is present, as a consequence of the use of peracetic acid as
the oxidation reagent [33]. Other minor glycoserine derivatives
are eluted before DIVa, with a similar retention time to DGlyser.
DGlyser may be one of these peaks, present in a small quantity,
however the other peaks detected are various glycoserine deriva-
tives modiﬁed by the puriﬁcation process. The large variety of
minor components observed requires use of a system similar to
that described in Fig. 3, where the molecular weight of each com-
ponent is linked to a deﬁned chromatographic time range. The val-
ues of Mw for unidentiﬁed compounds are given in relation to their
retention times on the chromatogram. In ﬁrst estimate, the reten-
tion on SAX chromatography for unsaturated disaccharides is gov-
erned by the sulfation pattern and more precisely, the number of
sulfates. The retention times of known disaccharides (DIVa, DIVs,
DIIa, DIIIa,DIIs,DIIIs,DIa andDIs) is partially correlated with their
molecular weights (Fig. 3). In the time ranges on the chromato-
gram corresponding to the transition between two disaccharides
with different Mw values (DIVs? DIIa , DIIIs? DIa, DIa? DIs),
it was chosen to follow this rule and give the average value of
the 2 bracketing disaccharide molecular weights. In addition, all
unidentiﬁed saccharides eluted after DIs were assigned, for the
sake of simplicity, with a molecular weight of 1228 Da. Fig. 5
shows chromatograms of heparin digests from porcine and bovine
origin. Each example has a speciﬁc disaccharide distribution. DIIIs,
DIa, and 3-O-sulfated residues from the 3 samples are very differ-
ent. Although the large proportion of galacturonic acid observed in
the heparin from bovine lung is related to the pronounced alkaline
step in the puriﬁcation process used, and not the species of origin,
this method can still be used as a simple and informative control toFig. 5. Comparison of digests from 3 heparins: (a) porcine intestinal mucosa; (b) bovine
(For interpretation of the references to colour in this ﬁgure legend, the reader is referrecheck at a ﬁrst glance what is the animal origin of a heparin sample
[7]. Crude and pure heparin batches purchased are periodically
analyzed by this technique to monitor product consistency against
preset criteria.
3.4. Quantiﬁcation of oligosaccharide building blocks
Quantiﬁcation is based on the consensus assumption about the
consistency of the molar response coefﬁcients at 232 nm [8,31],
and the maximum UV absorbance of unsaturated oligosaccharides
obtained after heparinase digestion. The principle and the chro-
matographic methods are identical to those used in the USP for
the quantiﬁcation of 1,6-anhydro derivatives in enoxaparin
[5,6,14,32].
The weight/weight (w/w) percentage for each component is
given by the following formula:
Component i % ðw=wÞ ¼ 100Mwi  Ai
RxMwx  Ax ð1Þ
Mwi and Ai are the molecular weight and the chromatographic area
at 232 nm of the assayed component i, respectively. Mwx and Ax are
the molecular weight and the chromatographic area, respectively, of
either the peak X or the zone X speciﬁed by its retention time; the
sum being related to all the eluted components.
The heparin batch from Fig. 3 was taken as an example for
building blocks quantiﬁcation in the Supplementary Data. The
method was entirely validated in its use for the titration of 1,6-
anhydro derivatives in enoxaparin. This validation has been pro-
vided to the USP and Ph. Eur. to support the introduction in the
monographs.lung; and (c) bovine intestinal mucosa. Black line: 232 nm; red line: 202–242 nm.
d to the web version of this article.)
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The SAX chromatographic method described in the USP and Ph.
Eur. pharmacopeias for the quantiﬁcation of 1,6-anhydro deriva-
tives in enoxaparin after digestion by heparinases [5,6] can also
be used to quantify the building blocks of heparin after its diges-
tion by a mixture of heparinases I, II, and III. In addition to the com-
positional assessment of the 8 naturally occurring building blocks
that can be used to identify the animal source, this method can be
used to detect markers of polysaccharide backbone denaturation
resulting from the heparin manufacture process as well as control
material consistency. Here we provide a comprehensive descrip-
tion of key manufacturing process ﬁngerprints, such as glycoserine
derivatives, 3-O-sulfated disaccharides and tetrasaccharides, des-
ulfated building blocks, and sulﬁte-modiﬁed disaccharides in order
to enable crucial analysis of heparin sources and suppliers.
Although not currently requested by the pharmacopoeias, it is
hoped that monitoring the building blocks and ﬁngerprints of hep-
arin will help safeguard its quality and ensure suitability for drug
product use. The method described here therefore provides a
heparinoid analysis technique complementary to 1H NMR spec-
troscopy, which strengthens the barriers against adulteration and
process deviations at any stage of heparin production and
LMWH-derived products.
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